Floatz logo

TTI-621

Human Papillomavirus-Related Malignant Neoplasm

PfizerPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Human Papillomavirus-Related Malignant Neoplasm cohort.

Asset / SponsorPhaseRating
Pegylated Interferon-Alpha-2A
Pfizer
Phase 1CC
T-Vec
Pfizer
Phase 1C

Same molecule, other indications

TTI-621 is also rated in:

cutaneous neuroendocrine carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
mycosis fungoidesDormant
CC
Indicative ·
41 / 100
View asset →
squamous cell carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →